Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
72 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Papillary Thyroid Cancer - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Papillary Thyroid Cancer - Pipeline Review, H2 2016, provides an overview of the Papillary Thyroid Cancer (Oncology) pipeline landscape. Papillary thyroid cancer, also known as papillary thyroid carcinoma, is the most common form of thyroid cancer. Symptoms include throat pain, difficulty swallowing or breathing and hoarse voice. Risk factors for papillary thyroid cancer include radiation exposure and a family history of thyroid cancer. Treatment includes chemotherapy, radiation therapy and surgery. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Papillary Thyroid Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Papillary Thyroid Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Papillary Thyroid Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Papillary Thyroid Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 6, 2 and 2 respectively for Papillary Thyroid Cancer. Papillary Thyroid Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Papillary Thyroid Cancer (Oncology). - The pipeline guide reviews pipeline therapeutics for Papillary Thyroid Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Papillary Thyroid Cancer (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Papillary Thyroid Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Papillary Thyroid Cancer (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Papillary Thyroid Cancer (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Papillary Thyroid Cancer (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Papillary Thyroid Cancer Overview 6 Therapeutics Development 7 Pipeline Products for Papillary Thyroid Cancer - Overview 7 Papillary Thyroid Cancer - Therapeutics under Development by Companies 8 Papillary Thyroid Cancer - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Papillary Thyroid Cancer - Products under Development by Companies 12 Papillary Thyroid Cancer - Companies Involved in Therapeutics Development 13 Blueprint Medicines Corporation 13 Daiichi Sankyo Company, Limited 14 Ignyta, Inc. 15 Novartis AG 16 Pfizer Inc. 17 Synactix Pharmaceuticals, Inc. 18 Vaccinex, Inc. 19 Papillary Thyroid Cancer - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 BLU-667 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 dabrafenib mesylate - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 entrectinib - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 everolimus - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 pasireotide - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 PLX-7486 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 PLX-8394 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 RXDX-105 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 sunitinib malate - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 SYN-001 - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 VX-15 - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 Papillary Thyroid Cancer - Dormant Projects 69 Papillary Thyroid Cancer - Discontinued Products 70 Appendix 71 Methodology 71 Coverage 71 Secondary Research 71 Primary Research 71 Expert Panel Validation 71 Contact Us 71 Disclaimer 72
List of Tables
Number of Products under Development for Papillary Thyroid Cancer, H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Late Stage Development, H2 2016 9 Comparative Analysis by Clinical Stage Development, H2 2016 10 Comparative Analysis by Early Stage Development, H2 2016 11 Products under Development by Companies, H2 2016 12 Papillary Thyroid Cancer - Pipeline by Blueprint Medicines Corporation, H2 2016 13 Papillary Thyroid Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 14 Papillary Thyroid Cancer - Pipeline by Ignyta, Inc., H2 2016 15 Papillary Thyroid Cancer - Pipeline by Novartis AG, H2 2016 16 Papillary Thyroid Cancer - Pipeline by Pfizer Inc., H2 2016 17 Papillary Thyroid Cancer - Pipeline by Synactix Pharmaceuticals, Inc., H2 2016 18 Papillary Thyroid Cancer - Pipeline by Vaccinex, Inc., H2 2016 19 Assessment by Monotherapy Products, H2 2016 20 Number of Products by Stage and Target, H2 2016 22 Number of Products by Stage and Mechanism of Action, H2 2016 24 Number of Products by Stage and Route of Administration, H2 2016 27 Number of Products by Stage and Molecule Type, H2 2016 29 Papillary Thyroid Cancer - Dormant Projects, H2 2016 69 Papillary Thyroid Cancer - Discontinued Products, H2 2016 70
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.